ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)
"Biotechnologia Acta" V. 9, No 3, 2016
https://doi.org/10.15407/biotech9.03.076
Р. 76-83, Bibliography 21, English
Universal Decimal Classification: 604.4.615.371
1 Kavetsky Institute of Experimental Pathology, Oncolongy and Radiobiology of the National Academy of Sciences of Ukraine, Kyiv
2 Taras Shevchenko National University of Kyiv, Ukraine
The aim of the research was to investigate the possibilities of increasing the efficiency of auto vaccinotherapy through the use of the endogenous interferon inductor amixin in mice with Lewis lung carcinoma. An effective plan for use of tumor vaccine and amixin, which is administered orally (25 mg/kg) for 3 hours before each of the five injections of the vaccine was developed. Its use in mice with transplanted Lewis lung carcinoma was significantly exceed the results of the introduction of anti-tumor vaccine alone: index of inhibition of tumor growth respectively 54.59 ± 1.97 and 43.79 ± 0.96%, and the average lifespan of mice – 56.2 ± 2.06 and 47.0 ± 1.50 days. In animals with minimal residual tumor (after surgical removal of the primary tumor) in adjuvant mode of antitumor vaccines amixin was effective with the introduction of the latter in the dose 3 hour before the vaccine or after 1 day after each introduction. The frequency of metastasis was decreased to 70%, the average number of metastases and their volume – 8.8 and 34.0% in comparison with those operated control mice, when compared to similar data of mice who received only the vaccine at 2.0 and 2.25 times. The index of inhibition of metastasis using a combined scheme was 92.6%, vaccine; alone vaccine – 83,08%. Further determination the mechanisms of synergistic effect antitumor vaccines and amixin will enable the use of different biopreparations and will help to develop effective schemes of therapy of cancer patients.
Key words: amixin, cancer vaccines, the Lewis lung carcinoma.
© Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, 2016
References
1. Dezfouli S., Hatzinisiriou I., Ralph S. J. Use of cytokines in cancer vaccines/immunotherapy: recent developments improve survival rates for patients with metastatic malignancy. Curr. Pharm. Des. 2005, 11 (27), 3511–3530.
2. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 2007, 18 (2), 226–232. https://doi.org/10.1093/annonc/mdl158
3. Belotskii S. M., Spivak N. Y. Interferons: biological and clinical effects. Kуiv. 2006, 287 p. (In Ukrainian).
4. Kirkwood J. Cancer immu notherapy: The interferon-a Experience. Semin. Oncol. 2002, 29 (3), suppl. 7, 18–26.
5. Zhilchuk V. Іе., Vorontsov A. L., Kudryavets Y. U. Y. Effect of neoadjuvant interferon therapy in pathomorphosis and immunochemical feat ures of breast cancer. Oncology. 2005, 7 (2), 157–160. (In Ukrainian).
6. Dillman R. O., Wiemann M., Nayak S. K, DeLeon C., Hood K., DePriest C. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group. J. Immunother. 2003, 26 (4), 367–373. PMID:12843799.
7. Abdel-Wahab Z., Weltz C., Hester D., Pickett N., Vervaert C., Barber J. R, Jolly D., Seigler H. F. A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer. 1997, 80 (3), 401–412. PMID: 9241074.
8. Pertseva T. A., Konopkin L. N. Interferons and their inducers. Ukrainian chemotherapeutic J. 2001, V. 2, Р. 62–67. (In Ukrainian).
9. Andronati S. A., Litvinova L. A., Golovenko G. Y. The oral inducer of endogenous interferon “ Amiksin “ and its analogs (review of the litera ture and our own research ). J. of Academy of Medical Sciences of Ukraine. 1999, 5 (1), 53–66. (In Ukrainian).
10. Fіlіpova T. O., Golovenko M. Y. Tilorone: profile of biological activity. I. Pharmacological properties. Іntehratyvna Anthropolohiia. 2006, 7 ( 1), 18–23. (In Ukrainian).
11. Kasihina C. Clinical application tilorona dihydrochloride: opportunities and prospects. Clin. Dermatol. Venerol. 2012, V. 2, Р. 66–74.
12. Chandra P., Wright G. J. Tilorone hydrochloride: the drug profile. Top. Curr. Chem. 1977, 72 (1), 125–148.
13. Chizhov N. P., Smolskaya, Baichenko P. I. Clinical studies of interferon ctivity and tolerability amiksina. Quest. Virol. 1990, 35 (5), 411–414 .
14. Kavetsky R. E., Balitchi K. P., Wexler I. G. Tilorona — synthetic immunopotentiator having antitumor activity. Probl. Oncol. 1977, 23 (11), 88–93. ( In Ukrainian).
15. Pinchuk V. G., Balitchi K. P., Wexler I. G. Antitumor Activity tilorona analogues and their combination with anticancer drugs. Chemotherapy of tumor s in the USSR. 1983, N 39, Р. 28–34. (In Russian).
16. Vaishampayan U., Abrams J., Darrah D., Jones V., Mitchell M. S. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin. Cancer Res. 2002, 8 (12), 3696–3701. PMID:12473578.
17. Vorontsovа A. L., Kudryavets Y. I. Interferon as an important element to optimize the treatment of cancer patients. Oncology. 2000, 2 (1–2), 16–20. (In Ukrainian).
18. Potebnya G. P., Kudryavets Yu. Y., Lisovenko G. S. Cheremshenko N. L., Voeykova I. M., Trokhimenko N. V., Symchich T. V., Evstrateyva L. M. Experimental study of the efficacy of combined use of cancer vaccine and interferon. Exp. Oncol. 29 (2), 102–105. PMID: 17704740.
19. Potebnya G. P., Voіеуkova І. M., Cheremshenko N. L. Improving the effectiveness of cancer vaccine probiotic drug Subalin. Onkologіya. 2008, 10 (2), 246–251. (In Ukrainian).
20. Patent of Ukraine N 57869. A method for producing anticancer autovaccine. Potebnya G. P., Lіsovenko G. S., Cheremshenko N. L., Tanasііеnko O. A., Chekhun V. F. Stated. 15. 06. 2001; Opubl. 15. 07. 2003; Byul. N 7. (In Ukrainian).
21. Perederiy V . G., Zemskov A. M., Bychkova N. G., Zemskov V. M. Immune status, the principles of evaluation and correction of immune disorders. Kуiv. 1995, Р. 61–62. (In Ukrainian)